Canada produces its first Canadian mRNA vaccines
Sept 5, 2025
Global Korean Post
–
Government of Canada on September 19, 2025 announced that Moderna has achieved a major milestone, producing the first made-in-Canada doses of its COVID-19 vaccine at its new state-of-the-art mRNA vaccine biomanufacturing facility in Laval, Quebec.
This milestone represents a concrete step forward in the government’s efforts to build a domestic vaccine supply chain. The new Laval facility will strengthen Canada’s ability to respond swiftly to public health emergencies.
Moderna’s operations in Canada, which also involve the establishment of domestic research and development partnerships and a partnership with Novocol Pharma’s fill-finish facility in Cambridge, Ontario, all underscore the company’s commitment to Canada’s life sciences industry, economic growth and scientific innovation.
The opening of Moderna’s facility and its production of domestically manufactured vaccines mark a new era of made-in-Canada innovation and biomanufacturing.
Since March 2020, over $2.5 billion has been invested in the Canadian biomanufacturing and life sciences sector, supporting 43 new and expanded projects to boost our domestic biomanufacturing, vaccine and therapeutics ecosystem.
Since its founding in 2010, Moderna has become a global leader in mRNA vaccine technology.
